SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
___________________
Date of Report (Date of earliest event reported) November 3, 1997
BIOCONTROL TECHNOLOGY, INC. (Exact name of registrant
as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address, if changes since last report.)
Item 1. Change in Control of Registrant. Not applicable.
Item 2. Acquisition or Disposition of Assets. Not applicable.
Item 3. Bankruptcy or Receivership. Not applicable.
Item 4. Changes in Registrant's Certifying Accountant Not applicable.
Item 5. Other Events. On November 3, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced today that in reaction to the Pittsburgh Post
Gazette's Sunday, November 2, 1997 article by Pat Sabatini the Company
is examining any and all possible legal remedies against both the Post
Gazette and Sabatini for the false and libelous allegations made
against the Company and several of its employees.
In addition, a letter is being sent to Dr. Bruce Burlington, Director,
Center for Devices and Radiological Health of the Food and Drug
Administration (FDA) as an invitation to come to the Indiana facility
to examine data and records for themselves.
Item 6. Resignation of Registrant's Directors. Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper, CEO
DATED: November 3, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release Release: Immediate
For More Information, Call: Investors
Media Diane McQuaide
Susan Taylor 1.412.429.0673 phone
1.412.279.9455 phone 1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL EXAMINING LEGAL ACTION AGAINST POST GAZETTE;
WILL HOLD SCIENTIFIC FORUM ON TECHNOLOGY
Pittsburgh, PA, November 3, 1997, Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that in reaction to the Pittsburgh Post
Gazette's Sunday, November 2, 1997 article by Pat Sabatini the Company is
examining any and all possible legal remedies against both the Post Gazette
and Sabatini for the false and libelous allegations made against the Company
and several of its employees.
In addition, a letter is being sent to Dr. Bruce Burlington,
Director, Center for Devices and Radiological Health of the Food and Drug
Administration (FDA), suggesting that prior to believing any accusations made
by Sabatini and the Post Gazette, they should come to the Indiana facility to
examine data and records for themselves.
Chief Executive Officer, Fred E. Cooper, said "Biocontrol takes such
accusations very seriously and intends to take any avenue possible to
demonstrate that they are false and merely a continuation of bitter former
employees taking revenge by using a member of the media known to give credence
to such questionable sources."
For reference, available from the Company at fax 412.279.9447 are the
questions submitted to Biocontrol by the Post and Sabatini prior to the
referenced article, Biocontrol's verbatim answers to those questions, and a
letter from Biocontrol's attorney that was sent to Sabatini with BICO's
answers.
The Company further announced that it will no longer stand for such
cheap shots by this media or any other and will therefore hold a scientific
forum to demonstrate and discuss at length the noninvasive technology
and its use in the Diasensor 1000 noninvasive glucose sensor for
diabetics. This forum will focus strictly on the scientific evaluation
of the technology. Invited to the seminar will be completely nonbiased
endocrinologists, chemometricians/mathematicians, diabetologists,
spectroscopists, diabetics, and parents of children with diabetes who
are qualified to understand the noninvasive technology and its
application for use in the Diasensor 1000. Also invited will be all
media, the FDA and all of the 1996 panel review members, the Juvenile
Diabetes Foundation, American Diabetes Association, the Pennsylvania
Securities Commission, Congressman Barton and the Oversight Committee,
Congressman Elizabeth Furse (head of the Congressional Diabetes
Committee). We will also make a point to invite Congressman Ron Klink,
Minority Chairman of the Oversight Committee. The scientific seminar
will be held as soon as the many schedules involved can be coordinated,
which could take a couple of months. Details will be released as they
are set, including the list of invitees, which will be published.
Biocontrol Technology, Inc. (www.bico.com) has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture of
biomedical devices and environmental products.
